Navigation Links
nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures

MORRISVILLE, N.C., Nov. 16 /PRNewswire/ -- nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for non-invasive treatment for heart conditions, today announced the initiation of a clinical trial designed to evaluate the safety and efficacy of its Numeris® - AF Tethered Coagulation System with VisiTrax® device in an open-chest concomitant procedure for the treatment of longstanding persistent atrial fibrillation (AF). This multi-center, non-randomized, prospective clinical trial will enroll up to 107 participants at 15 study sites across the United States.

"We developed our coagulation system based on the integration of suction, perfusion, and energy to create non-conductive, bi-atrial lesions. What is unique about this study is that we are creating a comprehensive lesion pattern on a beating heart to interrupt atrial fibrillation circuits located across both atria," said John P. Funkhouser, President and CEO of nContact. "Our hope is that this study will lead to participants being free from AF and completely off class I and class III antiarrhythmic drugs (AADs)* following their treatment."

The clinical trial procedure involves creating a bi-atrial lesion pattern on a beating heart to block electrical signals that cause AF. The lesions are created using nContact's tethered device on the upper chambers of the heart, the left and right atria, where the AF occurs. Once the lesions have been created, a cardiothoracic surgeon will be able to confirm intra-operatively through pacing whether the lesions are non-conductive and the pulmonary veins are isolated.

"The nContact technology enables me to create a comprehensive biatrial lesion pattern on a beating heart. We look forward to investigating the ability to treat atrial fibrillation in patients undergoing open heart surgery with the hope of establishing the lesion pattern with superior results," commented Dr. Edward Garrett, Jr., Principal Investigator from Baptist Memorial Hospital Heart Institute, Memphis.

For more information about the Numeris-AF Tethered Coagulation with VisiTrax trial, please visit (study number NCT00950092).

*The decision to stop the use of AADs will be decided by each participant's physician evaluation of the participant's medical status.

About nContact Surgical, Inc .

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF).

To date, The Numeris® Coagulation System with VisiTrax® is indicated for the coagulation of cardiac tissue (resulting in lesion creation) in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

    nContact, Inc.
    1001 Aviation Parkway, Ste 400
    Morrisville, NC  27560
    T (919) 466-9810
    F (919) 466-9811

    Media Contacts
    Angela Moser
    nContact Surgical, Inc.

    Scott Lerman
    The Ruth Group
    T (646) 536-7013

SOURCE nContact Surgical, Inc.

SOURCE nContact Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medicine Announces Strong Third Quarter 2009 Results
2. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
3. Chindex International Announces Participation in Brean Murray, Carret & Co. 2009 China Growth Conference
4. LifeCare Holdings, Inc. Announces Third Quarter Results
5. Telik Announces Third Quarter 2009 Financial Results
6. Quantros Announces Partnership With Hospital Accreditation Agency DNV
7. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
8. Dynatronics Announces Positive Financial Results for Quarter
9. Niusule Announces Key Additions to Management Team
10. Warner Chilcott Announces Secondary Equity Offering
11. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
Post Your Comments:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):